Background.
A national goal has been set to decrease inappropriate antibiotic use by 2020. To quantify decreases in use, consumption metrics and benchmarking strategies are implicit. However, while tracking and reporting antimicrobial use is widely recommended, these data do not address appropriateness. Accordingly, we developed a methodology to identify and report high and low vancomycin use periods which may represent inappropriate or unsafe antimicrobial use.
Methods. This is an observational, retrospective study of facility-wide vancomycin consumption data, aggregated, and examined on a hospital level from three academic medical centers: Northwestern Medicine (NM), Michigan Medicine (UM), and Henry Ford (HF) Hospital. Utilization was quantified as antimicrobial days (AD) per 1,000 days present (DP) on a monthly basis, recorded over 46 consecutive months (January 2014 through October 2017) for NM and HF, and 40 consecutive months (July 2014 through October 2017) for UM. Linear regression models and prediction intervals were generated to identify high-usage months. Use exceeding the upper bound of a prediction interval of 80 percent in a given month was used to define increased use, and the lower bound was used to define decreased use.
Results. Vancomycin use averaged 70.3 AD per 1,000 DP at NM, 89 at UM, and 153.8 at HF. Regression models indicated HF and UM consumption decreased at a monthly rate of 1.2 AD per 1,000 DP and 0.1 AD per 1,000 DP, respectively, whereas NM use increased at a rate of 0.1 AD per 1,000 DP over the study period. Overall, we identified n = 6, n = 5 and n = 6 vancomycin increased use months and n = 7, n = 6 and n = 5 decreased use months at NM, UM and HF, respectively. Background. The general medicine (GMed) and hospitalist (Hosp) services use antimicrobials at a relatively high rate among our teaching services. It is currently unknown if there is a difference in antimicrobial prescribing between various learner levels or attending type at our institution.
Conclusion
Methods. We measured antimicrobial utilization between January 1, 2016 to April 22, 2018 (2.25 years) in our GMed services. Services are divided by resident-led and hospitalist only services. The GMed1 service is staffed by outpatient internists, the GMed2 service is split between geriatricians and hospitalists, and the GMed3 service is only hospitalists. The "A" service is junior residents while "B" is senior residents. We measured utilization using the WHO defined Days of Therapy (DOT) definition normalized per 1,000 patient-days (PD). Secondary analysis based on antibiotic breadth and route were analyzed by average DOT/1,000 patient-days.
Results. GMed services prescribed at a higher rate of DOT than hospitalist services over the study timeframe (809 vs. 645, P < 0.0001). Junior resident-led services (A) used more antimicrobials than senior resident-led services (B) (894 vs. 606, P < 0.0001). There were no significant prescribing differences between the 1, 2, and 3 services by different attending roles (840 vs. 775 vs. 797). Similar trends continue in secondary analysis with hospitalists prescribing a lower average DOT/1,000 PD of broad-spectrum antibiotics and A services prescribing higher rates of broad-spectrum, anti-MRSA, and anti-Pseudomonal therapy compared with B services (Table 1) . Conclusion. Antimicrobials were prescribed at a significantly higher rate in services associated with trainees than those without. Junior resident-led services prescribed at a significantly higher rate than services-led by a senior resident. Interventions to reduce unnecessary antimicrobial exposure should be targeted toward learners, especially junior trainees.
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Background. Antibiotic use metrics are utilized by antimicrobial stewardship programs to benchmark performance against peer institutions and inform stewardship efforts. Benchmarking requires risk adjustment for patient-and facility-level factors so that remaining differences are attributable only to prescribing practices. Antibiotics for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) are one of the most frequently used drug classes. Our objective was to identify predictors of anti-MRSA antibiotic use in a nationwide network of hospitals.
Methods. We used data from inpatient encounters at facilities participating in the Vizient data repository between January 1, 2016 and December 31, 2016. The outcome, anti-MRSA antibiotic use, was calculated as days of therapy per patient-days present for each encounter. We constructed a multivariable negative binomial regression model and assessed the following predictors for inclusion: age, sex, race, ethnicity, diagnosis related groups (DRGs), ICU days, admit month, facility bed size, facility teaching status, and region. A clinical framework was used to categorize DRGs based on risk of anti-MRSA antibiotic use. A backwards stepwise approach was used to identify the final model. We evaluated predictor effect size and significance, and assessed model fit using a deviance-based pseudo-R 2 .
Results. One hundred forty-five facilities representing 3,608,711 encounters met inclusion criteria. All predictors considered in our model were significant. Predictors with the greatest magnitude of association included DRG categories and patient age. The DRG categories with the strongest associations were DRGs for infections likely due to Staphylococcus aureus (RR = 1.66, P < 0.0001) or for diagnoses likely to receive long-term MRSA coverage (RR = 1.49, P < 0.0001). The age group with the strongest association was age 2-10 years (RR = 1.64; P < 0.001). The deviance-based pseudo-R October 6, 2018: 12:30 PM Background. Adherence to the Infectious Diseases Society of America (IDSA) guidelines for the treatment of diabetic foot infections (DFIs) has been associated with improved outcomes. Yet, compliance with these guidelines has been reported to be low. We initiated a quality improvement project aimed at improving guideline adherence for DFI management. Baseline results are reported here.
Adherence to Practice Guidelines for Treating Diabetic
Methods. We reviewed all hospitalized primary DFIs newly initiated on antibiotics over 1 year (July 2014 -June 2015 . We collected demographics, DFI severity per IDSA guidelines, antibiotic use, and microbiology data. Guideline adherence for culturing and empiric antibiotic choice (based on severity) was assessed per IDSA guidelines. We then created an institutional guideline and electronic order set with built-in clinical decision support. Educational lectures on DFI best practices were given to providers who commonly treat DFIs.
Results. One hundred seventy-seven DFI admissions were identified: 40% severe (n = 70), 47% moderate (n = 84), 8% mild (n = 14), and 5% with no evidence of infection (n = 9). Demographics: mean age 58 years; 68% male, mean HgbA1c 8.6%, length of stay 6.9 days, 3-year mortality 13%. Empiric antibiotic regimens were judged inappropriate in 36% (64/177) of cases. The most common reason for inappropriate antibiotic use was unnecessary coverage for Pseudomonas aeruginosa in 50% (54/107) of nonsevere cases. In 28% (39/140) of cases with an ulcer, wound or skin breakdown, a superficial swab culture was obtained which is inappropriate. Only 33.3% (n = 56) had a deep tissue culture obtained. In patients with deep tissue cultures, methicillin-resistant Staphylococcus aureus (MRSA) was found in 11% (6/56) of cases but covered for empirically in 88% (50/56). Pseudomonas was found in 2% (1/56) of cases but covered for empirically in 73% (41/56).
Conclusion. MRSA and Pseudomonas are uncommon DFI pathogens yet are frequently treated empirically. Inappropriate antibiotic use is often due to empiric coverage for Pseudomonas in nonsevere DFIs where it is a rare pathogen. Culture practices are also less than ideal with frequent superficial swabs and underutilization of deep cultures. Institutional guidelines were developed to specifically address these issues and data collection of the impact of this project is in process.
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